Back
BioMarin Pharmaceutical Inc (BMRN)
BiotechnologyBMRN · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$66.10
+1.61%Weekly undervalued picks
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$1.77
ROE
4.5%
Gross margin
51.2%
Debt/Equity
0.23x
Revenue growth
2.8%
BioMarin Pharmaceutical Inc — company intelligence
Earnings surprises
Q2 2026$0.73 vs $0.70 est+4.0%
Q1 2026$0.54 vs $0.77 est-29.5%
Q4 2025$-0.24 vs $0.64 est-137.7%
Q3 2025$-0.16 vs $0.38 est-142.2%
Analyst consensus · 33 analysts
26 Buy7 Hold0 Sell
Updated Aug 23, 2026
Insider activity · 90 days
9 buys0 sellsnet +67,410 shares
ANDERSON ELIZABETH MBuy 7,490 · Jun 2, 2026
Bodem Barbara W.Buy 7,490 · Jun 2, 2026
CLARK IAN TBuy 7,490 · Jun 2, 2026
Recent SEC filings
8-K — Material event reportAug 18, 2026
10-Q — Quarterly reportAug 6, 2026
8-K — Material event reportAug 6, 2026
Latest news
BioMarin Pharmaceutical (BMRN) Agrees $490 Million Deal For Oral Rare Bone Disease Program — Yahoo · 4d ago
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today — Yahoo · 6d ago
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases — Yahoo · 6d ago
BioMarin acquiring Alesta Therapeutics for $275 million — Yahoo · 6d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.